Skip to main content

Research Repository

Advanced Search

Irritable Bowel Syndrome

Ford, Alexander C.; Sperber, Ami D.; Corsetti, Maura; Camilleri, Michael

Irritable Bowel Syndrome Thumbnail


Authors

Alexander C. Ford

Ami D. Sperber

MAURA CORSETTI Maura.Corsetti@nottingham.ac.uk
Clinical Associate Professor

Michael Camilleri



Abstract

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder whose symptoms include abdominal pain associated with a change in stool form or frequency. The condition affects between 5% and 10% of otherwise healthy individuals in the community at any one point in time and, in most people, runs a relapsing and remitting course. The best described risk factor is acute enteric infection, but IBS is also more common in people with psychological co-morbidity, and in young adult females. The pathophysiology of IBS remains incompletely understood, but it is well established that there is disordered communication between the gut and the brain, leading to motility disturbances, visceral hypersensitivity, and altered central nervous system processing. Other less reproducible mechanisms may include genetic associations, alterations in gastrointestinal microbiota, and disturbances in mucosal and immune function. In most people the diagnosis can be made based on the clinical history, with limited, judicious, use of investigations, unless alarm symptoms such as weight loss or rectal bleeding are present, or there is a family history of inflammatory bowel disease or coeliac disease. Once the diagnosis is made, an empathetic approach is key, and can improve quality of life and symptoms, and reduce health care expenditure. The mainstays of treatment include patient education about the condition, dietary changes, soluble fibre, and antispasmodic drugs. Other treatments tend to be reserved for those with more severe symptoms; these include central neuromodulators, intestinal secretagogues, drugs acting on 5-hydroxytryptamine or opioid receptors, or minimally absorbed antibiotics (all of which are selected according to predominant bowel habit), and psychological therapies. The increased understanding of the pathophysiology of IBS in the last 10 years has led to a healthy pipeline of novel drugs in development.

Journal Article Type Review
Acceptance Date Jul 3, 2020
Online Publication Date Oct 10, 2020
Publication Date Nov 21, 2020
Deposit Date Jul 3, 2020
Publicly Available Date Apr 11, 2021
Journal Lancet
Print ISSN 0140-6736
Electronic ISSN 1474-547X
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 396
Issue 10263
Pages 1675-1688
DOI https://doi.org/10.1016/S0140-6736%2820%2931548-8
Public URL https://nottingham-repository.worktribe.com/output/4746852
Publisher URL https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31548-8/fulltext

Files





You might also like



Downloadable Citations